The following represents disclosure information provided by authors of this abstract. The program committee has reviewed all presenting author disclosure reports, identified potential conflicts of interest, and implemented strategies to manage those areas of conflict, where appropriate. All relationships are considered compensated. Relationships are self-held unless otherwise noted. I = Immediate Family Member, Inst = My Institution
 
Open Payments is a public database containing information reported by companies about payments made to US-licensed physicians (Open Payments)
Evaluation of drug tolerability as a function of toxicity and quality of life in patients enrolled on I-SPY2.
 
Amrita B. Basu
Travel, Accommodations, Expenses - Leidos Health
 
Saumya Umashankar
No Relationships to Disclose
 
Denise M. Wolf
No Relationships to Disclose
 
Hannah Chay
No Relationships to Disclose
 
Abigail Abikoye
No Relationships to Disclose
 
Thelma Brown
No Relationships to Disclose
 
Diane Heditsian
Stock and Other Ownership Interests - Johnson & Johnson
 
Susie Brain
No Relationships to Disclose
 
Tina J. Hieken
Research Funding - Genentech/Roche (Inst); Skyline Diagnostics (Inst)
 
Kathryn Jean Ruddy
Research Funding - Medtronic (I)
Patents, Royalties, Other Intellectual Property - Spouse and Mayo Clinic have filed patents related to the application of artificial intelligence to the electrocardiogram for diagnosis and risk stratification. (I)
 
Sarah Tevis
No Relationships to Disclose
 
Anne Hudson Blaes
Research Funding - Dompé Farmaceutici
 
Shelly S. Lo
No Relationships to Disclose
 
Rita Nanda
Consulting or Advisory Role - AstraZeneca; Daiichi Sankyo/Astra Zeneca; Exact Sciences; GE Healthcare; Gilead Sciences; Guardant Health; Merck; Moderna Therapeutics; Novartis; Sanofi; Seagen; Stemline Therapeutics
Research Funding - Arvinas (Inst); AstraZeneca (Inst); Celgene (Inst); Corcept Therapeutics (Inst); Genentech/Roche (Inst); Immunomedics (Inst); Merck (Inst); OBI Pharma (Inst); Odonate Therapeutics (Inst); OncoSec (Inst); Pfizer (Inst); Relay Therapeutics (Inst); Seagen (Inst); Sun Pharma (Inst); Taiho Oncology (Inst)
Other Relationship - G1 Therapeutics
 
Christina Yau
Patents, Royalties, Other Intellectual Property - U.S. Provisional Application No. 63/314,065 (Inst); U.S. Provisional Application No. 63/341,579 (Inst)
 
Michelle E. Melisko
Stock and Other Ownership Interests - Merrimack (I)
Speakers' Bureau - AstraZeneca (I); Genentech (I); Gilead Sciences (I)
Research Funding - DAEHWA Pharmaceutical (Inst); Novartis (Inst); OBI Pharma (Inst)
Patents, Royalties, Other Intellectual Property - Multiple patents related to immunoliposomal drugs being studied and potentially brought to market by Merrimack (I)
Expert Testimony - GlaxoSmithKline
 
David Cella
Stock and Other Ownership Interests - FACIT.org
Consulting or Advisory Role - Abbvie; Astellas Pharma; Bristol-Myers Squibb; Celcuity; Fulcrum Therapeutics; Immunogen; Ipsen; Novartis; Pfizer
Research Funding - Abbvie (Inst); Bristol-Myers Squibb (Inst); Clovis Oncology (Inst); Ipsen (Inst); Novartis (Inst); Pfizer (Inst); PledPharma (Inst)
 
Laura Esserman
Consulting or Advisory Role - Blue Cross Blue Shield Association
Research Funding - Moderna Therapeutics (Inst)
Travel, Accommodations, Expenses - Blue Cross Blue Shield Association
(OPTIONAL) Uncompensated Relationships - Quantum Leap Healthcare Collaborative
 
Hope S. Rugo
Consulting or Advisory Role - Daiichi Sankyo; Eisai; Mylan; Napo Pharmaceuticals; Puma Biotechnology
Research Funding - Astellas Pharma (Inst); AstraZeneca (Inst); Daiichi Sankyo (Inst); Gilead Sciences (Inst); GlaxoSmithKline (Inst); Hoffmann-La Roche AG/Genentech, Inc (Inst); Lilly (Inst); Merck (Inst); Novartis (Inst); OBI Pharma (Inst); Pfizer (Inst); Stemline Therapeutics (Inst); Taiho Oncology (Inst); Veru (Inst)
 
Dawn L. Hershman
Consulting or Advisory Role - AIM Specialty Health